Compare Abbott Laboratories (ABT) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Palantir Technologies Inc — how do they compare? Abbott Laboratories trades at $95.42 (market cap $166.94B), while Palantir Technologies Inc trades at $130.32 (market cap $322.13B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| ABT | PLTR | |
|---|---|---|
Market Cap | $166.94B | $322.13B |
Sector | Health | Technology |
52-Week High | $136.62 | $207.18 |
52-Week Low | $82.57 | $107.27 |
Enterprise Value | $193.69B | $314.31B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PLTR trades at $134.37, up 4.03% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $4.48B in 2025, with net income reaching $1.63B, though valuation ratios remain elevated. Recent news highlights AI partnerships with Nvidia and expansion in Mexico, driving positive sentiment.
Outlook is positive given robust earnings growth and AI adoption, but high P/E of 148.92 poses valuation risk. Analyst consensus price target is $185.67, with 46% buy ratings. Key risks include competitive pressures and reliance on government contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
